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Abstract Growth hormone deficiency is common in
intracranial tumors, which is usually treated with surgery
and radiotherapy. A number of previous studies have
investigated the relationship between the growth hormone
replacement therapy (GHRT) and risk of tumor recurrence/
progression; however, the evidence remains controversial.
We conducted a meta-analysis of published studies to
estimate the potential relation between GHRT and
intracranial tumors recurrence/progression. Three compre-
hensive databases, PUBMED, EMBASE, and Cochrane
Library, were researched with no limitations, covering all
published studies till the end of July, 2014. Reference lists
from identified studies were also screened for additional
database. The summary relative risks (RR) and 95 %
confidence intervals (CI) were calculated by fixed-effects
models for estimation. Fifteen eligible studies, involving
more than 2232 cases and 3606 controls, were included in
our meta-analysis. The results indicated that intracranial
tumors recurrence/progression was not associated with
GHRT (RR 0.48, 95 % CI 0.39–0.56), and for children, the
pooled RR was 0.44 and 95 % CI was 0.34–0.54. In sub-
group analysis, risks of recurrence/progression were
decreased for craniopharyngioma, medulloblastoma,
astrocytoma, glioma, but not for pituitary adenomas, and
non-functioning pituitary adenoma (NFPA), ependymoma.
Results from our analysis indicate that GHRT decreases the
risk of recurrence/progression in children with intracranial
tumors, craniopharyngioma, medulloblastoma, astrocy-
toma, or glioma. However, GHRT for pituitary adenomas,
NFPA, and ependymoma was not associated with the
recurrence/progression of the tumors. GH replacement
seems safe from the aspect of risk of tumor progression.
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Introduction
Surgical resection, radiotherapy, and chemotherapy are
currently some of the most efficient treatment methods for
brain tumors [1]. However, complications resulting from
the management of the tumor are serious, such as growth
hormone deficiency (GHD). GHD is often found in tumors
post-irradiation or tumors related to sella turcica, such as
pituitary adenomas and craniopharyngioma. Growth hor-
mone (GH) plays a significant role in metabolism. It reg-
ulated fuel homeostasis and promotes growth through
glycometabolism, lipid metabolism, and protein anabolism
[2]. Thus, continued exogenous GH infusion is considered
in GHD patients, especially those having a disorder of
metabolism or a low quality of life.
The safety of GHRT in tumor management remains
controversial. Three hundred sixty one children, enrolled in
the Childhood Cancer Survivor Study, were treated with
GH. The rate ratio of GHRT survivors developing a second
neoplasm, as compared to no-GHRT survivors, was 2.15
(95 % CI 1.3–3.5) [3]. Furthermore, in patients with pro-
longed critical illness, high doses of GH are associated with
increased morbidity and mortality [4]. However, recent
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studies have demonstrated that long-term GH use in
hypopituitarism may be considered safe in patients with
central nervous system (CNS) tumors [5–7]. However, the
role of GHRT toward the progression of CNS tumor in
patients remained poorly understood. Therefore, we con-
ducted a meta-analysis of published observational studies
to validate the role of GH in intracranial tumors.
Materials and methods
Research strategy
Reviewers (LS and CMS) performed a systematic literature
search independently from three databases, PUBMED,
EMBASE, and Cochrane Library for published studies
without limitations. Reviewers used the following terms as
research strategy: ([MeSH] ‘‘brain neoplasms’’ or ‘‘in-
tracranial tumors’’ or ‘‘seller tumors’’ or ‘‘brain tumors’’)
and ([MeSH] ‘‘growth hormone’’ or ‘‘growth hormone
deficiency*’’ or ‘‘growth hormone replacement therapy’’ or
‘‘GH replacement therapy’’ or ‘‘GHRT’’), and ([MeSH]
‘‘recurrence’’ or ‘‘recurrence’’ or ‘‘progression’’ or ‘‘en-
largement’’). No limitations were imposed. A manual
search of identified articles’ references was performed for
additional studies.
Study selection
The studies were selected using the following criteria: (1)
case–control study or cohort design; (2) intracranial tumors
treated with growth hormone; (3) relationship between
GHRT and recurrence/progression of intracranial tumors
was assessed; (4) values of RRs and the corresponding
95 % CIs or sufficient data were estimated; and (5) study
with largest sample size or the most recent study in meta-
analysis if the same study population was published several
times was chosen.
Data extraction and methodological assessment
The following data were independently extracted from of
the participants involved in the study: surname of the first
reviewer, publication year and country of literature, age at
diagnosis of subjects in the study, numbers of case and
control groups, follow-up and GH therapy years, methods
of recurrence/progression diagnosis, and study quality.
Methodological quality was evaluated standardly by two
observers using the Newcastle-Ottawa Scale (NOS) criteria
[8]. NOS included three steps: (1) subject selection, 0–4;
(2) comparability of subject, 0–2; and (3) clinical outcome,
0–3. The NOS scores ranged from zero to nine. A score of
six or more indicated a good quality; otherwise, the study is
deemed to have relatively lower quality. All the disagree-
ments were resolved carefully by two reviewers through
discussion.
Statistical analysis
The STATA software (Version 12.0, Stata Corporation,
College Station, TX, USA) was used for the analysis. RR
values and the corresponding 95 % CI were used to estimate
the relationship between GHRT and risk of recurrence/
progression in intracranial tumors with GHD. Heterogene-
ity, in the analysis, was evaluated by the Q statistic and I2
statistic [9, 10]. Heterogeneity was tentatively assigned
with the values corresponding to middle heterogeneity and
notable heterogeneity: I2 values \30 and [50 % [9].
p[ 0.1 for the Q statistic or I2\ 50 % for the I2 statistic
were considered statistically insignificant [10]. If hetero-
geneity was indicated, random-effect model was used;
otherwise, fixed-effect model was employed [11]. More-
over, subgroup analyses were performed to explore poten-
tial factors for heterogeneity. In order to assess the stability
of each study for the overall estimation, sensitivity and
publication bias analyses were conducted as described
previously [11]. For the best possible information available,
more than one method for bias was conducted for assess-
ment, for example Egger’s test and Begg’s funnel plot [12,
13]. Briefly, sensitivity analysis was employed to assess the
impact of individual study on the overall estimation.
Results
Literature search and study characteristics
Figure 1 summarizes the flow chart of literature search and
selection. A total of 524 articles were selected for identi-
fication. Fifteen studies, published from 1985 to 2013, were
selected in the meta-analysis. Of the 15 studies, six were
carried out from UK, three from USA, two from Germany,
two from Sweden, one from Norway, and one from
Canada. Additional characteristics of the included studies
are shown in Table 1. As shown in table, seven of the
selected studies obtained seven or more scores, which
indicated that the study quality was relatively higher [5–7,
14–22]; whereas, other studies with relatively lesser scores
were considered of lower quality [23–25].
Correlation of GHRT- and GH-deficient
intracranial tumors
Different types of GH-deficient intracranial tumors were
researched in the studies. As shown in forest plots, the
pooled RR for GHRT versus no-GHRT was 0.48 (95 % CI
1860 Neurol Sci (2015) 36:1859–1867
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0.39–0.56; I2 = 14.7 %, p for heterogeneity = 0.285) for
all types of GH-deficient intracranial tumors (Fig. 2).
GHRT and risk of tumor recurrence/progression
in children
Seven studies supported the available information on the
risk of tumor recurrence/progression in children treated
with GH. The pooled RR was 0.44 (95 % CI 0.34–0.54;
I2 = 0.0 %, p for heterogeneity = 0.680) (Fig. 3). Figure 3
represents the information on infants and older children.
Subgroup analysis
GHRT for craniopharyngioma
A total of four studies [7, 21, 22, 26] in our meta-analysis
estimated the risk of craniopharyngioma. Figure 4 shows
the forest plots for craniopharyngioma recurrence/pro-
gression in individuals with and without GHRT. The
combined RR for GH use was 0.43 (95 % CI 0.28–0.67;
I2 = 31.2 %, p for heterogeneity = 0.225).
GHRT for pituitary adenomas
Four studies [5, 19, 20, 22] assessed the relationship
between GHRT and risk of recurrence/progression in
pituitary adenomas. The cumulative estimated risk associ-
ated with GH use was 0.85 (95 % CI 0.65–1.11;
I2 = 16.6 %, p for heterogeneity = 0.309). For NPFA, the
risk was 0.93 (95 % CI 0.70–1.25; I2 = 0.0 %, p for
heterogeneity = 0.403) (Fig. 4).
GHRT for brain tumors
As shown in Fig. 5, the combined RR for medulloblastoma
was 0.27 (95 % CI 0.17–0.42; I2 = 3.7 %, p for hetero-
geneity = 0.374). RRs for ependymoma and astrocytoma
were 0.87 (95 % CI 0.52–1.47; I2 = 0.0 %, p for hetero-
geneity = 0.536) and 0.51 (95 % CI 0.29–0.93;
I2 = 0.0 %, p for heterogeneity = 0.675), respectively.
Ependymoma and astrocytoma were part of glioma, and the
pooled RR for glioma was 0.64 (95 % CI 0.45–0.90;
I2 = 22.8 %, p for heterogeneity = 0.274).
Sensitivity analysis and publication bias
For sensitivity analysis, we left out each of the studies, in
turn, to investigate the influence of a single study on the
overall risk estimation. In Fig. 6, the corresponding RRs
for GHRT versus no-GHRT were not significantly altered.
The Begg’s funnel plot showed that the RR values were
symmetrical. The results from the Egger’s test suggested
that there was no pronounced publication bias (p for
Egger’s test of all types of intracranial tumors, and tumors
in children were 0.453 and 0.121, respectively).
Discussion
While hypothalamus and pituitary axis were blocked or
broken because of tumor, surgical resection, radiotherapy,
and GHD occurred with serious clinical symptoms, such as
increased morbidity. GH was injected to balance the
endocrine system. However, infused GH raised the serum
Fig. 1 Flow chart of literature
selection
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concentration of insulin-like growth factors-1 (IGF-1),
which stimulated cell proliferation and inhibited apoptosis
[27].
In the analysis of association between GHRT and GH-
deficient intracranial tumors, results have indicated that
GHRT was correlated with a decrease risk of tumor
recurrence/progression. In the subgroup analyses,
decreased risks were also obtained from craniopharyn-
gioma, medulloblastoma, astrocytoma, and glioma. Irrele-
vant risks of tumor recurrence/progression were acquired
from pituitary adenomas, NFPA, and ependymoma. How-
ever, the fluctuation in serum levels of GH and IGF-1 was
observed in neoplastic disease, which might affect tumor
progression [28]. In addition, Renehan et al. conducted a
Table 1 Characteristics of studies included in the meta-analysis






















10.8 ± 2.2 13/21 NR NR NR Medulloblastoma, glioma 6
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et al. [25], UK





NR NR Medulloblastoma, glioma,
others
8
Packer et al. [15],
Canada
\15 545 5 NR NR Medulloblastoma 7
Sklar et al. [16],
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\17.2 172/1489 6.2 4.6 NR Medulloblastoma, glioma 8
Hatrick et al.
[17], UK








32/53 10.8 ± 9.2a
8.3 ± 8.8b
6.3 ± 4.6 CT MRI Craniopharyngioma 8
Buchfelder et al.
[19], Germany
NR 55/55 5 8.2 ± 6.7 MRI Pituitary adenomas 8




121/114 9.9 ± 3.9
10.1 ± 4.4
10 ± 4 CT MRI Pituitary adenomas 7





























56/70 13.6 ± 5.0a
13.4 ± 7.8b
13.6 ± 5.0 CT MRI Craniopharyngioma 7
Hartman et al.
[22], USA
NR 1309/339 2.3 ± 1.4a
2.3 ± 1.6b
0.5–1 NR Pituitary adenomas,
craniopharyngioma. others
6
CT computed tomography, F female, MRI magnetic resonance imaging, M male, NR not reported
a Case group
b Control group
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meta-regression analysis and demonstrated that high level
of IGF-1 contributed to carcinogenesis in prostate, col-
orectal, and premenopausal breast cancers [29]. However,
the results from intracranial tumors treated with GH indi-
cated that GHRT was not associated with increased risk of
recurrence/progression. During the period of GH treatment,
the dose of GH was adjusted regularly depending on serum
level of IGF-1 [5]. Thus, in patients treated with GH, the
level of GH was elevated in accordance with the normal
reference levels of IGF-1. Berg et al. confirmed that IGF-1
levels were influenced by several factors other than GH
[30]. GH was found to induce high levels of IGF-1 in many
malignancies [31, 32]. In our meta-analysis, most of tumors
were benign. Renehan et al. also demonstrated that high-
normal levels of IGF-1 had no influence on post-
menopausal and lung cancer [29]. From this inconformity,
GH might promote the progression of some of the tumors,
but not all. It was undeniable that heterogeneity resulted in
varied effects of tumors on same interventions.
More detailed information on age, which was major risk
factor for tumors, was taken into consideration. Results
have confirmed that GHRT in children decreased the risk
of tumor recurrence/progression (RR 0.44, 95 % CI
0.34–0.54). No sufficient evidence from the studies indi-
cated that GH promoted the progression of intracranial
tumors [14, 16, 25]. Ergun-Longmire et al. performed a
retrospective study with 361 survivors treated with GH,
and confirmed that these survivors were easier to trap in
second neoplasms (RR 3.21) [3, 16]. Recent studies have
reported no statistically significant increase in the risk of
occurrence of the CNS subsequent neoplasms with GH
exposure [33]. Equivocal conclusion on the issue was
addressed by assessing the current resource. CNS tumors
are a heterogeneous family of neoplasms that differ in
tissue origins, degree of apoptosis, amplification, and
invasive potential, especially during prognosis. Segregation
of varied tumors and randomized controlled trials would be
beneficial to confirm the potential relationship between GH
treatment and second neoplasms.
Most of our studies included were retrospective in nat-
ure. Thus, some of the influencing factors were unavoid-
able. Additionally, years of follow-up were not equal or
were too short. The optimum duration of recurrence/pro-
gression was probable beyond the follow-up period. The
segregation of varied tumors with enough patients was
required. Moreover, selection and publication bias in the
Fig. 2 Forest plot of GHRT and tumor recurrence/progression in GH-deficient intracranial tumors
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Fig. 3 Forest plot of GHRT and tumor recurrence/progression in children
Fig. 4 Forest plot of GHRT and tumor recurrence/progression in craniopharyngioma, pituitary adenomas, and NFPA
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Fig. 5 Forest plot of GHRT and tumor recurrence/progression in medulloblastoma astrocytoma, and glioma
Fig. 6 Sensitivity analyses for
GHRT and no-GHRT for
intracranial tumors
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meta-analysis because of non-random samples and
unpublished literatures.
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